Managing comorbid disease in patients with psoriatic arthritis

被引：26

作者：

Husni M.E. ^{[1
]}

Mease P.J. ^{[2
]}

机构：

[1] Cleveland Clinic, Orthopedic and Rheumatologic Institute, Cleveland, OH 44195

[2] Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA

来源：

Current Rheumatology Reports | 2010年 / 12卷 / 4期

关键词：

Cardiovascular disease; Comorbidities; Depression; Infection; Malignancy; Obesity; Osteoporosis; Psoriasis; Psoriatic arthritis;

D O I：

10.1007/s11926-010-0112-3

中图分类号：

学科分类号：

摘要：

Psoriatic arthritis (PsA) is a unique type of inflammatory arthritis that is associated with skin psoriasis. The concept that PsA is simply a skin and joint disease has been challenged by large epidemiologic studies that link PsA with substantial comorbidity. Important comorbidities related to PsA include premature cardiovascular disease, infectious complications, malignancy risk, osteoporosis, and reduced quality of life. This review focuses on the prevalent comorbid diseases in patients with PsA and highlights how the presence of these associated comorbidities can affect the management of these patients. © 2010 Springer Science+Business Media, LLC.

引用

页码：281 / 287

页数：6

共 37 条

[21]

Sattar N., Crompton P., Cherry L., Et al., Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study, Arthritis Rheum, 56, pp. 831-839, (2007)

[22]

Strober B., Teller C., Yamauchi P., Et al., Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis, Br J Dermatol, 159, pp. 322-330, (2008)

[23]

Channual J., Wu J.J., Dann F.J., Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis, Dermatol Ther, 22, pp. 61-73, (2009)

[24]

Saraceno R., Schipani C., Mazzotta A., Et al., Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis, Pharmacol Res, 57, pp. 290-295, (2008)

[25]

Gelfand J.M., Gladman D.D., Mease P.J., Et al., Epidemiology of psoriatic arthritis in the population of the United States, J Am Acad Dermatol, 53, (2005)

[26]

Husted J.A., Gladman D.D., Farewell V.T., Cook R.J., Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis, Arthritis Rheum, 45, pp. 151-158, (2001)

[27]

Burmester G.R., Mease P., Dijkmans B.A., Et al., Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases, Ann Rheum Dis, 68, pp. 1863-1869, (2009)

[28]

Spadaro A., Scrivo R., Spinelli F.R., Valesini G., Monitoring biological therapies in psoriatic arthritis, J Rheumatol Suppl, 83, pp. 69-70, (2009)

[29]

Askling J., Van Vollenhoven R.F., Granath F., Et al., Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment?, Arthritis Rheum, 60, pp. 3180-3189, (2009)

[30]

Rohekar S., Tom B.D., Hassa A., Et al., Prevalence of malignancy in psoriatic arthritis, Arthritis Rheum, 58, pp. 82-87, (2008)

← 1 2 3 4 →